OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.

ABSTRACT:

Background

Initial evidence that OPRM1 genotype moderates the clinical response to naltrexone has not been replicated in prospective clinical trials. However, the use of traditional statistical analyses and clinical endpoints might limit sensitivity for studying pharmacogenetic associations, whereas the use of intensive daily assessments and person-centered analytic methods might increase sensitivity. This study leveraged person-centered analyses and daily measures of alcohol use, craving, and medication adherence to investigate OPRM1 as a moderator of changes in clinical outcomes during naltrexone treatment.

Methods

Treatment-seeking participants with alcohol use disorder (n = 58; M_age  = 38 years; 71% male) provided daily cell phone reports of craving and consum

SUBMITTER: Hendershot CS 

PROVIDER: S-EPMC8758337 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature